四价登革热疫苗效力试验的中和抗体相关分析:亚洲与拉丁美洲
在CYD14和CYD15三期试验中,CYD-TDV疫苗对第13至25个月症状性病毒学确诊登革热的效力分别为56.5%和60.8%。第13个月中和抗体滴度较高者,同血清型VCD风险显著降低(风险比0.19-0.43每10倍升高),且四血清型平均滴度较高者VE显著更高(P<.001)。
要点
- 第13个月同血清型中和抗体滴度每升高10倍,VCD风险比为0.19-0.43。
- 四血清型平均滴度较高者,任何血清型VCD的疫苗效力显著更高(P<.001)。
- 最低滴度不完全对应零效力,提示其他因素影响疫苗效力。
核心结论
- 第3剂后中和抗体滴度与CYD-TDV预防登革热的效力相关,高滴度在所有血清型、基线血清状态组、年龄组及两项试验中均与高效力相关,但最低滴度不完全对应零效力。
研究设计与样本
- CYD14和CYD15三期试验的中和抗体相关分析,在第13个月随机抽样免疫原性子队列及截至第25个月所有VCD病例中测量4种登革热血清型中和抗体滴度(疫苗2848例,安慰剂1574例)。
主要发现
- 每项试验每种血清型中,第13个月同血清型滴度较高的受种者该血清型VCD风险显著更低(风险比0.19-0.43每10倍升高)。
- 每项试验中,第13个月四血清型平均滴度较高的受种者任何血清型VCD的VE显著更高(P<.001)。
局限性
- 最低滴度不完全对应零效力,提示其他因素影响VE。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the CYD14 and CYD15 Phase 3 trials of the CYD-TDV dengue vaccine, estimated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue (VCD) occurring between months 13 and 25 was 56.5% and 60.8%, respectively. METHODS: Neutralizing antibody titers to the 4 dengue serotypes in the CYD-TDV vaccine insert were measured at month 13 in a randomly sampled immunogenicity subcohort and in all VCD cases through month 25 (2848 vaccine, 1574 placebo) and studied for their association with VCD and with the level of VE to prevent VCD. RESULTS: For each trial and serotype, vaccinees with higher month 13 titer to the serotype had significantly lower risk of VCD with that serotype (hazard ratios, 0.19-0.43 per 10-fold increase). Moreover, for each trial, vaccinees with higher month 13 average titer to the 4 serotypes had significantly higher VE against VCD of any serotype (P < .001). CONCLUSIONS: Neutralizing antibody titers postdose 3 correlate with CYD-TDV VE to prevent dengue. High titers associate with high VE for all serotypes, baseline serostatus groups, age groups, and both trials. However, lowest titers do not fully correspond to zero VE, indicating that other factors influence VE.
引用
- Moodie Z, Juraska M, Huang Y, et al. Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. J Infect Dis. 2018. PMID: 29194547. doi:10.1093/infdis/jix609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。